公开(公告)号：US20230210860A1

公开(公告)日：2023-07-06

申请号：US17818294

申请日：2022-08-08

Applicant: Shionogi & Co., Ltd. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Takeki UEHARA ,  Toru ISHIBASHI ,  Takao SHISHIDO ,  Keita FUKAO ,  Motoyasu OONISHI ,  Barry CLINCH ,  Jaspinder RANDHAWA

IPC: A61K31/5383 ,  A61K31/215 ,  A61P31/16

CPC classification number: A61K31/5383 ,  A61K31/215 ,  A61P31/16

Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

公开(公告)号：US20230233573A1

公开(公告)日：2023-07-27

申请号：US18192491

申请日：2023-03-29

Applicant: SHIONOGI & CO., LTD.

Inventor： Takao SHISHIDO ,  Keita FUKAO ,  Takeshi NOSHI ,  Yoshinori ANDO ,  Takahiro NODA

IPC: A61K31/5383 ,  A61P31/16 ,  A61K9/00 ,  A61K9/06 ,  A61K9/28 ,  A61K9/48 ,  A61K9/70 ,  A61K31/245 ,  A61K45/06

CPC classification number: A61K31/5383 ,  A61P31/16 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/007 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/282 ,  A61K9/2826 ,  A61K9/4858 ,  A61K9/7007 ,  A61K31/245 ,  A61K45/06

Abstract: A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.

公开(公告)号：US20220008429A2

公开(公告)日：2022-01-13

申请号：US16825263

申请日：2020-03-20

Applicant: Shionogi & Co., Ltd. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Takeki UEHARA ,  Toru ISHIBASHI ,  Takao SHISHIDO ,  Keita FUKAO ,  Motoyasu OONISHI ,  Barry CLINCH ,  Jaspinder RANDHAWA

IPC: A61K31/5383 ,  A61K31/215 ,  A61P31/16

Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

公开(公告)号：US20240285643A1

公开(公告)日：2024-08-29

申请号：US18602656

申请日：2024-03-12

Applicant: Shionogi & Co., Ltd. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Takeki UEHARA ,  Toru ISHIBASHI ,  Takao SHISHIDO ,  Keita FUKAO ,  Motoyasu OONISHI ,  Barry CLINCH ,  Jaspinder RANDHAWA

IPC: A61K31/5383 ,  A61K31/215 ,  A61P31/16

CPC classification number: A61K31/5383 ,  A61K31/215 ,  A61P31/16

Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

公开(公告)号：US20210228590A1

公开(公告)日：2021-07-29

申请号：US17204246

申请日：2021-03-17

Applicant: SHIONOGI & CO., LTD.

Inventor： Takao SHISHIDO ,  Keita FUKAO ,  Takeshi NOSHI ,  Yoshinori ANDO ,  Takahiro NODA

IPC: A61K31/5383 ,  A61P31/16 ,  A61K9/00 ,  A61K9/28 ,  A61K9/48 ,  A61K9/06 ,  A61K31/245 ,  A61K45/06 ,  A61K9/70

Abstract: A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.

公开(公告)号：US20200297731A1

公开(公告)日：2020-09-24

申请号：US16825263

申请日：2020-03-20

Applicant: Shionogi & Co., Ltd. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Takeki UEHARA ,  Toru ISHIBASHI ,  Takao SHISHIDO ,  Keita FUKAO ,  Motoyasu OONISHI ,  Barry CLINCH ,  Jaspinder RANDHAWA

IPC: A61K31/5383 ,  A61K31/215 ,  A61P31/16

Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.